drugset / Trial / NCT07022223
Orelabrutinib Combined With Rituximab as First-line Systemic Treatment for Marginal Zone Lymphoma
Phase 2
Recruiting
51 enrolled
Second Affiliated Hospital, School of Medicine, Zhejiang University
Affiliated Hospital of Jiaxing University · collabDongyang People's Hospital · collabHuzhou Central Hospital · collabNingbo People's Hospital · collabSecond Affiliated Hospital of Wenzhou Medical University · collabShaoxing Central Hospital · collabShaoxing People's Hospital · collabTaizhou First People's Hospital · collabTaizhou Hospital · collabTaizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University · collabThe Central Hospital of Lishui City · collabThe People's Hospital of Quzhou · collabThe Second Affiliated Hospital of Jiaxing University · collabYuyao People's Hospital · collabZhejiang Cancer Hospital · collabZhejiang University · collabZhuji People's Hospital of Zhejiang Province · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a single-arm, prospective clinical study to evaluate the efficacy and safety of orelabrutinib combined with rituximab as first-line systemic treatment for marginal zone lymphoma.
Timeline
- Start
- 2025-03-11
- Primary completion
- 2027-09-11
- Completion
- 2029-09-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Orelabrutinib | Small molecule | 150 mg | Oral |
| Subject | Rituximab | Monoclonal antibody | 375 mg/m2 | — |